Member Info for Sandhopper

RNS Number : 8994V
MC Mining Limited

12 August 2020

ANNOUNCEMENT

12 August 2020

CONDITION SATISFIED FOR THE ISSUE OF NEW EQUITY

Further to the announcement published on 21 July 2020, MC Mining Limited ("MC Mining" or the "Company") is pleased to confirm South Africa Reserve Bank approval for the issue of new equity ("New Equity") for a collective R15.0 million ($0.9 million*). This satisfies the condition required for the issue of the New Equity comprising 13,331,433 new ordinary shares in the Company. The New Equity will be issued at an agreed price of 105.56 SA cents/ 6.27 pence (United Kingdom).

A commitment for the issue of the New Equity was a condition in the R40 million ($2.4 million) restructured loan agreement (the "Agreement") with the Industrial Development Corporation of South Africa Limited ("IDC") to advance the Makhado hard coking coal project ("Makhado Project") and for general working capital. In terms of the Agreement, the IDC will receive an estimated 1.1 million warrants, equating to 0.8% of MC Mining's issued shares, and its direct participation in the Makhado Project will increase from 5% to 6.7%.

Application will be shortly made for the admission of the 13,331,433 new ordinary shares to trading on AIM, the ASX and the JSE and an announcement will be made in due course. Following admission of the New Equity, the Company will have 154,419,555 ordinary shares in issue, such figure can be used as the denominator for the calculations by which a shareholder will determine if they are required to notify their interest in, or a change to their interest in the Company, under the ASX Listing Rules or the DTRs.

Brenda Berlin

Acting Chief Executive Officer

Hi ivans,
I just tried to get in to a link which lead me to the Hardman August 2020 Report, and now it's telling me my Browser is no longer supported and I need to get a more up to date Browser to continue !!

TISSUE REGENIX
Investment programme initiated
TRX is focused on the development and commercialisation of two proprietary
decellularisation technology platforms for repair of soft tissue (dCELL) and bone
(BioRinse). Its broad portfolio of commercialised regenerative medicine products
is targeting the biosurgery, orthopaedics and dental markets. Over the past two
years, the company has revised its commercial strategy, realigned its supply chain,
and restructured operations to service the strong product demand and overcome
capacity constraints. The recent equity raise has provided the capital needed for the
phased capacity expansion and sufficient working capital for the foreseeable future.
? Strategy: TRX is building an international regenerative medicine business around
its proprietary technology platforms, underpinned by compelling clinical outcomes.
It plans to develop production capabilities, enabling the business to expand its
global distribution network, via strategic partnerships, to drive sales momentum.
? Interims: Despite the fact that TRX has had to contend with operational,
financing, a cyber security incident and COVID-19-related issues, we believe
that the company will deliver broadly flat sales for 1H’20. The main driver has
been the delay to elective procedures in the US due to COVID-19.
? Expansion: The tangible benefits of increasing to two-shift manufacturing in
San Antonio, coupled with outsourcing some DermaPure production, only
began to materialise in 4Q’19. Phased investment has commenced to increase
the number of clean rooms in San Antonio, which should benefit from 1H’21.
? Risks: With proper funding now in place, the main risk is timing and commercial
execution. As with all businesses, the impact of the current global COVID-19
pandemic is unquantifiable until there is further clarity around timing and the
effect on elective surgical procedures.
? Investment summary: TRX has a portfolio of innovative regenerative products
with regulatory approval in both the US and EU. Realignment of the commercial
strategy to maximise sales potential through strategic and distribution partnerships
has been successful, resulting in increased demand for products. Having
secured the required funding to invest in scaling the manufacturing facilities, the
market will start to take note when management delivers on future milestones.
Financial summary and valuation
Year-end Dec (£m) 2017 2018 2019 2020E 2021E 2022E
Sales 5.23 11.62 13.03
EBITDA -9.01 -7.09 -6.13
Underlying EBIT -9.72 -8.27 -7.18
Reported EBIT -10.82 -8.69 -7.20
Underlying PBT -9.67 -8.46 -7.64
Forecasts under review
Statutory PBT -10.77 -8.88 -7.66
Underlying EPS (p) -0.90 -0.67 -0.60
Statutory EPS (p) -1.02 -0.70 -0.61
Net (debt)/cash 16.42 7.82 0.09
Equity issues 40.25 0.00 0.00
P/E (x) - - -
EV/sales (x) - 2.3 1.1
Source: Hardman & Co Life Sciences Research

As are the majority of companies, as it's all just emerging. Not knowing for sure, but it felt like DB had ironed out most of the awkward problems but BB does sound to be "pushing on" from where DB had "stalled". Let's hope we will all get renewed hope , as you say, in the next 90. GLA

Hi Jantand, wish I had the money to buy a decent 'stack' of shares around that price as the most expensive purchase I made that is still in my portfolio was made pre-consolidation on 31/01/2013, the recalculated amount of shares are 387.5, and I need a price of 464.2p to break even (which is never going to happen) so must add more at these prices to "help the cause" !!

The SELL of 5268 shares @ 5.7499p at 16:11 this afternoon is my BUY. Just rounded off a holding in one of my a/c's

Shares not in public hands as at 20 July 2020 - 3,697,608,659 - 52.58%

Shares not in public hands as at 06 July 2020 - 2,931,471,473 - 41.68%

I see Lombard Odier Asset Management (Europe) Limited have increased their holding from 14.04% to 15.03%

the Market is "managing" this share until their "agenda" has been satisfied. How long are they going to "manage" the sp is the 64 million dollar question everyone would like to know. Sit tight, have patience, and reap the rewards when this "agenda" has been satisfied. GLA

Let's hope so chester. Looks like that "bus driver" is still looking for 1st gear so as we can get going.

Just added a small amount (125000 @ .334p) at 09-56am, and it's showing as a sell.

Tue, 21st Jul 2020 09:00
RNS Number : 5402T
MC Mining Limited

21 July 2020

ANNOUNCEMENT 21 July 2020

CONDITION SATISFIED FOR THE DRAW DOWN OF THE IDC LOAN

Got an email from Paragon Bank telling me they are taking another 25% off the rate I am getting on some savings - so What the Heck, after saying earlier this morning I had reached my target holding here so wouldn't add more, then decided to take another 250,000 after all. The £825 I spent here would have earnt me £6-19p before tax in 12 months with Paragon, but I think I can safely say 250,000 shares bought today @ 0.33p will be giving me a 'tad' better return over the next 12 months !!

Just gives us a little more confidence now that we have a couple of big names building positions. I feel like adding some more but having now reached my target holding (how many times have I said that before) and should refrain from spending any more dosh.

Morning chester,

Yes a bit confusing until you either try a dummy sell or buy. Just done a dummy sell and was offered .3376p. Haven't tried a dummy buy as I used up all my funds yesterday adding more @ .3399p

Yep Boz, the small one of 4732 @ 6.15p is mine. Had an odd £300 sitting in my ISA so thought I would add a few here.

Bit of useless information really - for all of you who look out for RNS's that are released at 07-00am each trading day like I do, then not one of the last 12 (twelve) RNS's that TRX has released has been at / or anywhere near 07-00am !!.

Was looking to add to my holding this afternoon, and had four attempts but didn't buy as each time I was quoted 'dearer' than the previous, which bucks the trend as of late - didn't add in the end - so let's see what next week brings, and if it gets even dearer, then I will be very happy as it might mean we have turned that corner - at last !!

Have a good week-end ALL

IP Group 13.66
Lombard Odier Asset Management 13.26
Premier Miton Group plc 10.87
Richard Griffiths 6.93
Spreadex Ltd 5.31
Jupiter Asset Management 4.86
Directors and Related Holdings 3.90

Shares not in public hands as at 06 July 2020 - 2,931,471,473 - 41.68%
Shares in issue as at 06 July 2020 - 7,032,985,756 ordinary shares of 0.1p each

Even though the future looks much brighter now the funding news has been sorted for the next 18 months or there abouts, the share price was never going to ‘zip’ back up to 1p/2p.

It’s only my opinion, but with so many cheap shares having been bought, and the ex-Woodford holding still gradually being sold, then this will be a bit of a slow climb away from these present levels. Any of us LTH’s looking to get our invested money back are going to have “the patience of a saint” as the saying goes.

We can deal with the patience side; it’s the time it takes which we have no control over for us “old wrinkles’ which is not on our side. Good Luck to all the “old wrinkles” and me of course.